Nicholas R Livingston, Amanda Kiemes, Gabriel A Devenyi, Samuel Knight, Paulina B Lukow, Luke A Jelen, Thomas Reilly, Aikaterini Dima, Maria Antonietta Nettis, Cecilia Casetta, Tyler Agyekum, Fernando Zelaya, Thomas Spencer, Andrea De Micheli, Paolo Fusar-Poli, Anthony A Grace, Steve C R Williams, Philip McGuire, Alice Egerton, M Mallar Chakravarty, Gemma Modinos
Elevated hippocampal perfusion has been observed in people at clinical high risk for psychosis (CHR-P). Preclinical evidence suggests that hippocampal hyperactivity is central to the pathophysiology of psychosis, and that peripubertal treatment with diazepam can prevent the development of psychosis-relevant phenotypes. The present experimental medicine study examined whether diazepam can normalize hippocampal perfusion in CHR-P individuals. Using a randomized, double-blind, placebo-controlled, crossover design, 24 CHR-P individuals were assessed with magnetic resonance imaging (MRI) on two occasions, once following a single oral dose of diazepam (5 mg) and once following placebo...
April 24, 2024: Neuropsychopharmacology